Drugs that contain Dapagliflozin; Metformin Hydrochloride

1. List of Xigduo Xr drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(2 years from now)

US7919598 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Dec, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Jun, 2027

(4 years from now)

US8685934 ASTRAZENECA AB Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof
May, 2030

(7 years from now)

US9616028 ASTRAZENECA AB Bilayer tablet formulations
Nov, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Oct 18, 2022
M Feb 22, 2022

Market Authorisation Date: 29 October, 2014

Treatment: Treatment of type 2 diabetes mellitus; Treatment of type 2 diabetes mellitus in a patient, wherein glycemic control (hba1c < 7.0%) is not achievable using one or more of insulin, metformin, pioglitazone, or rosiglitazone

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of XIGDUO XR before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic